Losartan Potassium CAS 124750-99-8 API Factory Antihypertensive High Purity
Nikeza ngeLosartan Potassium kunye neMiphakathi eNxulumeneyo noMgangatho oPhezulu
I-Losartan Potassium CAS 124750-99-8
I-2-Butyl-4-Chloro-5-Formylimidazole (BCFI) CAS 83857-96-9
| Igama leMchiza | Losartan Potassium |
| Izithethantonye | DUP 753;eCozaar;2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]imidazole-5-methanol Potassium Ityuwa |
| Inombolo yeCAS | 124750-99-8 |
| Inombolo yeCAT | RF-API98 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C22H22ClKN6O |
| Ubunzima beMolekyuli | 461.01 |
| Indawo yokunyibilika | 263.0~265.0℃ |
| Ukunyibilika | Inyibilika ngokukhululekileyo emanzini nakwiMethanol, iNyibilika kancinane kwiAcetonitrile. |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe okanye ophantse wamhlophe |
| Isazisi A | I-Infrared Absorption: Kufuneka ifane noMgangatho weReferensi |
| Isazisi B | Ukufunxwa kwe-Ultraviolet: Kufuneka kufane noMgangatho weReferensi |
| Uvavanyo lwePotassium | Kufuneka ube Pozitive |
| Isiqulatho samanzi (KF) | ≤0.50% |
| Iintsimbi ezinzima | ≤10ppm |
| Izinto eziyeleleneyo (HPLC) | |
| Nakuphi na Ukungacoceki komntu | ≤0.20% |
| Ukungcola ngokupheleleyo | ≤0.50% |
| Intsalela yezinyibilikisi (GC) | |
| Cyclohexane | ≤0.10% |
| Isopropyl Utywala | ≤0.20% |
| Indlela yoVavanyo / yoHlalutyo | I-98.5 ~ 101.0% (i-HPLC, ibalwa kwisiseko se-anhydrous, i-solvent-free basis) |
| N-Nitrosodiethylamine | ≤0.177ppm (NDEA) |
| N-Nitrosodimethylamine | ≤0.640ppm (NDMS) |
| Ubungakanani beNcam | 90% Ngaphantsi kwe-38 Microns |
| Beka ubomi kwishelufa | Iinyanga ezingama-24 |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | I-API, i-Angiotensin II Receptor Antagonist Antihypertensive |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Losartan Potassium yeyokuqala enamandla kwaye ikhetha i-non-peptide i-angiotensin II ye-receptor uhlobo loku-1 (AT1) i-antagonist eyaziswa kwimarike njenge-antihypertensive yomlomo yomlomo kanye yonke imihla.Uxinaniso oluvimbela i-50% yokubopha i-angiotensin II (IC50) yi-20 nM.I-Losartan (40 μM) ichaphazela i-ISC kodwa ikhusela umphumo we-ANGII kwi-ISC.I-Losartan inciphisa kakhulu ukwanda kweeseli ze-Ang II kwiiseli zomhlaza we-endometrial.Indibaniselwano ye-losartan kunye ne-anti-miR-155 inefuthe elikhulu kakhulu lokuchasana ne-antiproliferative xa kuthelekiswa neyeza ngalinye lodwa.I-metabolized ukuvelisa i-5-carboxylic acid metabolite (EXP3174) kwaye ixelwe ukunciphisa uxinzelelo lwegazi.Okwangoku iphandwa njengonyango olunokubakho lwe-COVID-19 ukuze ikwazi ukunciphisa okanye ukuthomalalisa iimpawu ze-COVID-19.
1. Kunyango lwe-hypertension efunekayo, inokusetyenziswa yodwa okanye idibene namanye amachiza e-antihypertensive (njenge-diuretics).2. Kunyango lokungaphumeleli kwentliziyo, inokusetyenziswa yodwa okanye ngokudibanisa ne-cardiotonic okanye i-diuretic Chemicalbook drugs.3. Ukuthintela i-stroke kwizigulane ezine-hypertension kunye ne-left ventricular hypertrophy.4. Isetyenziselwa ukucotha ukuqhubela phambili kwe-nephropathy kwizigulane ezinesifo sikashukela sohlobo lwe-2 ezinxulumene ne-nephropathy kunye noxinzelelo lwegazi.
